Masterclass series in peripheral arterial disease

Criqui MH , Fronek A , Barrett-Connor E , Klauber MR , Gabriel S , Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-515.

Leng GC , Lee AJ , Fowkes FGR et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25: 1172-1181.

Fowkes FGR. Epidemiology of atherosclerotic arterial disease in the lower limbs. Eur J Vasc Surg 1988; 2: 293-291.

Wood D , Durrington P , Poulter N , McInnes G , Rees A , Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (suppl 2): S1-S29.

Levine GN , Keaney JF Jr , Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332:512-521.

Chen ZM , Peto R , Collins R , MackMahon S , Lu JR , Li WX. Serum cholesterol concentration and coronary heart disease in populations with low cholesterol concentrations. BMJ 1991; 303:276-282.

Pedersen TF , Kjeksus J , Berg K et al for the Scandinavian Simvastatin Survival Study Group . Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study. Lancet 1995; 345: 1274-1275.

Sacks FM , Pfeffer MA , Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.

Tonkin A , Kirby A , Newman P et al. Pravastatin reduces the high rate of atherothrombotic complications in coronary heart disease patients with intermittent claudication. J Am Coll Cardiol 2001; 37 (2 suppl A).

Aronow WS , Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and seum low density lipoprotein cholesterol 125mg=dl or more treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90:789-791.

Heart Protection Study Collaborative Group . MRC=BHF Heart protection study of cholesterol lowering with simvastatin in 20-536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360:7-22.

Grobbee DE , Bots ML. Statin treatment and progression of athero-sclerotic plaque burden (Review). Drugs 2003; 63: 893-911.

Pederson TR , Kjekshus J , Pyorola K et al. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998; 81: 333-335.

Mohler ER 3rd , Hiatt WR , Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with PAD. Circulation 2003; 108: 1481-1486.

Mondillo S , Balio P , Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolaemic patients with peripheral vascular disease. Am J Med 2003: 114:359-363.

Shepherd J , Blauw GJ , Murphy MB et al. Pravastatin in elderly individuals at risk of cardiovascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.

Williams D , Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.

Meade T , Zuhrie R , Cook C , Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139-1139.

Leng GC , Price JF , Jepson RG. Lipid lowering therapy for lower limb atherosclerosis (Cochrane Review). In: Cochrane Library, Issue 3, 2003. Oxford: Update Software.

Tang TJ , Armitage JM , Lancaster Y , Silagy CA , Fowler GH , Neil HAW. Systematic review of dietary intervention trials to lower blood cholesterol in free-living subjects. BMJ 1998; 316: 1213-1219.

Executive summary of the third report of the National Cholesterol Education Program (NCEP) . Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel-III). JAMA 2001; 285: 2468-2497.

Hirsch AT , Gotto AM. Under treatment of dyslipidaemia in peripheral arterial disease and other high risk populations: an opportunity for cardiovascular disease reduction. Vasc Med 2002; 7:323-331.

Cassar K , Belch JJF , Brittenden J. Are national cardiac guidelines being applied by vascular surgeons? Eur J Vasc Endovasc Surg 2003; 26: 623-628.